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Viral hepatitis and Parkinson disease
A national record-linkage study
ABSTRACT
Objective: To study associations between viral hepatitis and Parkinson disease (PD).
Methods: A retrospective cohort study was done by analyzing linked English National Hospital
Episode Statistics and mortality data (1999–2011). Cohorts of individuals with hepatitis B,
hepatitis C, autoimmune hepatitis, chronic active hepatitis, and HIV were constructed, and com-
pared to a reference cohort for subsequent rates of PD.
Results: The standardized rate ratio (RR) of PD following hepatitis B was 1.76 (95% confidence
interval [CI] 1.28–2.37) (p , 0.001), based on 44 observed compared with 25 expected cases.
The RR of PD following hepatitis C was 1.51 (95% CI, 1.18–1.9) (p , 0.001), based on 48.5
expected and 73 observed cases. There was no significant association between autoimmune
hepatitis, chronic active hepatitis or HIV, and subsequent PD. When including only those episodes
of care for PD that occurred first at least 1 year following each exposure condition, the RR for
hepatitis B and hepatitis C were 1.82 (1.29–2.5) and 1.43 (1.09–1.84), respectively.
Conclusions: We report strong evidence in favor of an elevation of rates of subsequent PD in pa-
tients with hepatitis B and hepatitis C. These findings may be explained by factors peculiar to viral
hepatitis, but whether it reflects consequences of infection, shared disease mechanisms, or the
result of antiviral treatment remains to be elucidated. Further work is needed to confirm this asso-
ciation and to investigate pathophysiologic pathways, potentially advancing etiologic understand-
ing of PD more broadly. Neurology® 2017;88:1630–1633
GLOSSARY
CI 5 confidence interval; HCV 5 hepatitis C virus; HES 5 English National Hospital Episode Statistics; ICD-10 5 Interna-
tional Classification of Diseases–10; PD 5 Parkinson disease; RR 5 rate ratio.
Parkinson disease (PD) is a common neurodegenerative disease characterized by motor and non-
motor symptoms, with loss of dopaminergic neurons in the substantia nigra pars compacta and
presence of Lewy body pathology.1 The etiopathogenesis of the disease is complex, and multiple
risk factors have been identified including advancing age, male sex, environmental toxins, and
head trauma.1 Two epidemiologic studies based in Taiwan have recently added to an existing
body of case reports reporting an association between hepatitis C and risk of PD.2,3 In one of
these, a nationwide cohort study utilizing the Taiwan National Health Insurance Research
Database, an adjusted hazard ratio of PD following hepatitis C of 1.29 (95% confidence interval
[CI] 1.06–1.56) was observed.2 Neither study found evidence of a relationship between hepatitis
B virus and PD following adjustment for potential confounding factors. We used a linked
dataset of English national hospital records to study associations between viral hepatitis and
PD, and we speculate whether any such relationship may be a reflection of viral hepatitis
specifically, hepatitis more generally, or the use of antiviral therapy.
METHODS Population and data. English National Hospital Episode Statistics (HES) were analyzed in conjunction with mor-
tality data to conduct a retrospective cohort study across 1999–2011. Utilizing HES records encompassing all episodes of day-case
or inpatient care in all National Health Service hospitals in England, we built cohorts of individuals with hepatitis B, hepatitis C,
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autoimmune hepatitis, chronic active hepatitis, and HIV by
identifying the first episode of day-case or inpatient admission in
which each of these conditions was coded (whether as the prin-
cipal cause for the admission, or in any diagnostic position) (ICD-
10 codes used in construction of exposure cohorts are found in
the table footnotes). Individuals admitted for a variety of rela-
tively minor medical and surgical conditions (table footnotes)
were extracted to build a reference cohort. Individuals with
a preexisting or co-occurring admission for PD at the time of first
exposure condition were excluded.
Statistical methods. Date of entry into each of the cohorts was
taken as the date of first recorded episode of day-case or inpatient
care for the exposure or reference conditions. Date of first re-
corded episode for PD, death, or the reach of end of data col-
lection constituted the date of cohort exit (whichever was
earliest). Analyses of PD rates were stratified, and standardized, in
5-year age groups, by sex, calendar year of first recorded admis-
sion (for exposure and reference conditions), residential area, and
quintile of socioeconomic status (as estimated by the standard
English measure of Index of Deprivation score). Indirect stan-
dardization was applied, in which the standard population
comprised the combined exposure and reference cohort. Stratum-
specific rates in the standard population were applied to the
number of person-days in each corresponding stratum of each
exposure cohort and then, separately, to those in the corre-
sponding stratum in the reference cohort, to calculate the ex-
pected number of cases of PD in each stratum in each cohort. In
each cohort, the observed and expected numbers in each stratum
were summed to provide the total for the cohort. Where O and E
represent the observed and expected numbers of PD in both the
exposure and reference cohorts, the formula (OHEP/EHEP)/(OREF/
EREF) provides the rate ratios (RRs). The methodology used in the
calculation of CIs for RRs and calculation of x2 statistics in
assessment of significance, and more detailed methods of ana-
lytical technique, has been described elsewhere.4
Standard protocol approvals, registrations, and patient
consents. The build and use of the datasets for multipurpose
research received ethical approval from the Central and South
Bristol Research Ethics Committee (04/Q2006/176).
RESULTS There were 21,633, 48,428, 6,225,
4,234, and 19,870 individuals in the hepatitis B, hep-
atitis C, autoimmune hepatitis, chronic active hepati-
tis, and HIV cohorts, respectively. A total of
6,132,124 individuals were in the reference cohort.
The standardized RR of PD following hepatitis B
was 1.76 (95% CI 1.28–2.37). The RR of PD fol-
lowing hepatitis C was 1.51 (95% CI 1.18–1.9)
(table). There were no significant elevations of PD
rates in the autoimmune hepatitis, chronic active hep-
atitis, or HIV cohorts. In aiming to reduce the pos-
sibility of surveillance bias and of reverse causality, we
subsequently included only those episodes of care for
PD that occurred first at least 1 year following each
exposure condition, and found a consistently elevated
PD risk following hepatitis B and hepatitis C (table).
DISCUSSION We report evidence supporting a sig-
nificantly increased risk of PD in patients with hepa-
titis B or C. Significant associations between
autoimmune hepatitis, chronic hepatitis, or HIV
and PD were not observed. These findings may be ex-
plained by a specific aspect of viral hepatitis (rather
than a general hepatic inflammatory process or gen-
eral use of antivirals) but whether this reflects shared
disease mechanisms, shared genetic or environmental
Table Rate ratios (RRs) and 95% confidence intervals (CIs) for Parkinson disease (PD) in people with hepatitis
or HIV compared with the reference cohort
Exposure Overall outcome Observed Expected RR (95% CI) p Value
Hepatitis B PD 44 25.0 1.76 (1.28–2.37) ,0.001
Hepatitis C PD 73 48.5 1.51 (1.18–1.90) ,0.001
Autoimmune hepatitis PD 16 10.1 1.59 (0.91–2.58) 0.087
Chronic active hepatitis PD 18 15.7 1.15 (0.68–1.81) 0.652
HIV PD 16 13.7 1.16 (0.67–1.89) 0.635
Exposure
Outcome at
least 1
year after first
exposure
admission Observed Expected RR (95% CI) p Value
Hepatitis B PD 38 20.9 1.82 (1.29–2.50) ,0.001
Hepatitis C PD 59 41.3 1.43 (1.09–1.84) 0.008
Autoimmune hepatitis PD 13 7.4 1.76 (0.94–3.00) 0.061
Chronic active hepatitis PD 13 13.7 0.95 (0.51–1.63) 0.961
HIV PD 12 12.3 0.98 (0.50–1.70) 0.954
Exposure cohorts ICD-10 codes used were hepatitis B B16.0-B16.9, B18.0-B18.1; hepatitis C B17.1, B18.2; autoimmune
hepatitis K75.4; chronic active hepatitis K73.2; HIV B20-B24; PD G20. Conditions used in the reference cohort were as
follows: cataract, otitis externa/media, varicose veins, hemorrhoids, deflected nasal septum, nasal polyp, inguinal hernia,
ingrowing toenail and other diseases of nail, sebaceous cyst, internal derangement of knee, bunion, appendectomy, hip
replacement, knee replacement, gallbladder disease.
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susceptibility, sequelae of viral hepatitis per se, or
a consequence of treatment remains to be deter-
mined. These findings are in line with the recently re-
ported association between hepatitis C and PD in
Taiwan, but contrast with the finding of no associa-
tion with hepatitis B.2,3 Explaining a relationship
between viral hepatitis and PD is largely speculative.
Neurotropic features of hepatitis C have been
described previously and include the potential for
cognitive impairment, independent of hepatic
encephalopathy.5 Further, all essential hepatitis C
virus (HCV) receptors have been shown to be ex-
pressed on the brain microvascular endothelium,
which constitutes the primary component of the
blood–brain barrier, thus suggesting one mechanism
by which the virus may affect the CNS.6 This notion
has been supported by the detection of HCV RNA
sequence in a small study of postmortem brain tissue
from infected patients.7 A study in rats, with and
without hepatitis C, found evidence of neuronal
toxicity (60% dopaminergic neuron death) induced
by the virus in a midbrain neuron–glia co-culture
system.3 Intriguingly, parkinsonism during combi-
nation treatment with pegylated interferon-a and
ribavirin, commonly used in chronic HCV, has been
described. There was no improvement following
termination of HCV treatment, but clinical benefit
was observed with use of levodopa, and symptom
relapse upon tapering.8 In considering interferon as
a potential contributory factor, in the Taiwanese
community-based study (2000–2004) most hepatitis
C–infected patients would not have been exposed to
interferons (only reimbursed in Taiwan for HCV
from 2004), making interferon unlikely to have an
important role, at least in their data.3 We note that
the rate of autoimmune hepatitis and PD was close to
reaching statistical significance in this study, and thus
influence of a common factor between autoimmune
and viral hepatitis is possible. Parkinsonism in the
context of liver cirrhosis is recognized and thought to
be independent from hepatic encephalopathy–
associated cognitive impairment. At least in some
cases, this may be secondary to manganese deposi-
tion. We did not adjust our analyses for prevalent
cases of cirrhosis because clinical data on the presence
of cirrhosis was not available to us. We consider it
likely that there may be many patients with hepatitis
and secondary cirrhosis who never have their cirrhosis
coded as a separate diagnosis in hospital, and the use
of a day-case or inpatient hospital record with an
ICD-10 code for cirrhosis is hence considered an
unreliable tool in considering the potential presence
of cirrhosis-related parkinsonism.
Limitations include that we were unable to control
for lifestyle factors such as smoking or alcohol. How-
ever, notably, smokers have higher rates of viral
hepatitis but lower rates of PD (and thus would
potentially mask any positive association between
viral hepatitis and PD), and the association between
alcohol and PD is unclear but suggests no relationship
or a reduced rate of PD with high alcohol consump-
tion.9,10 The use of routinely collected hospital data
also means that detailed clinical data, such as that
needed to confirm a PD diagnosis beyond it having
been clinically coded, were not available to us. There-
fore we are not able to rule out that our findings could
be explained by an increased association with
cirrhosis-related parkinsonism, and not PD. How-
ever, given the rare occurrence of cirrhosis-related
parkinsonism, we find this unlikely. This is also not
a follow-up study from the point of first diagnosis:
entry into the exposure and reference cohorts is based
upon the first recorded episode of hospital care for the
respective conditions. We assume that the majority of
patients with PD will have been coded in hospital at
least once. The numbers of PD cases were often small,
even when drawing upon a population of 50 million;
and this study should be considered as best that could
be done using a very large national hospital dataset of
the HES type. As it is a hospital-based study, it is not
possible to exclude the potential presence of selection
bias compared to a community-based study, and it is
possible that patients included in this study may rep-
resent those at the more severe end of disease spec-
trum. We have aimed to mitigate this as best as
possible through the inclusion of a reference cohort
that is also hospital-based.
We report evidence in favor of elevated rates of sub-
sequent PD in patients with hepatitis B and hepatitis
C. Acknowledging constraints of routinely collected
data, we suggest that this may reflect factors associated
specifically with viral hepatitis or its treatment. We
encourage further work confirming this association or
contributing insight into potential pathophysiologic
pathways, which may be important in understanding
the development of PD more broadly.
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